Edwards Lifesciences Corporation ($EW) Stock Forecast: Up 5.1% Today

What is Edwards Lifesciences Corporation?

Edwards Lifesciences Corp. (EW) is a medical research company that focuses on heart valves and hemodynamic monitoring. The stock had a strong bullish movement today amidst a generally positive trading session in the market.

Why is Edwards Lifesciences Corporation going up?

EW stock is up 5.1% on Jun 16, 2026 14:00

• Edwards Lifesciences Corp. (EW) experienced a noteworthy increase in its stock price, surpassing the broader market indices.
• Sector Gamma AS and other institutional investors acquiring additional shares in EW could be seen as a vote of confidence in the company's future outlook.
• The favorable sentiment towards EW might be linked to anticipated progress in heart valve technology or positive advancements in the company's pipeline.
• Despite the upward trend, the stock exhibited lower performance compared to the overall market, suggesting potential for further growth and opportunities for market catch-up.

EW Price Chart

EW Technical Analysis

EW News

Edwards Lifesciences Corp. stock rises Monday, still underperforms market

Edwards Lifesciences Corp. (EW) shares increased by 1.37% on Monday, closing at $86.28. This rise occurred during a generally favorable trading session where the S&P 500 Index and Dow Jones Industrial Average also saw gains. Despite the positive movement, the stock's performance still lagged behind the broader market.

https://www.marketwatch.com/data-news/edwards-lifesciences-corp-stock-rises-monday-still-underperforms-market-bc822c9d-28b80f43a009?mod=mw_quote_news

Blackhill Capital Inc. Has $3.78 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Blackhill Capital Inc. has reduced its stake in Zimmer Biomet Holdings, Inc. by 21.9% to 42,079 shares, valued at approximately $3.78 million. Despite mixed analyst ratings and an insider stock sale, Zimmer Biomet reported strong quarterly earnings, surpassing revenue and EPS estimates. The company also announced a quarterly dividend of $0.24, payable on July 31st.

https://www.marketbeat.com/instant-alerts/filing-blackhill-capital-inc-has-378-million-position-in-zimmer-biomet-holdings-inc-zbh-2026-06-14/

First National Bank of Omaha Takes $8.92 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

First National Bank of Omaha recently acquired a new stake of 98,467 shares, valued at approximately $8.92 million, in Zimmer Biomet Holdings, Inc. during the fourth quarter. This move is part of broader institutional interest, with several other hedge funds also increasing their holdings in the medical equipment provider, bringing total institutional ownership to 88.89%. Despite this, analysts maintain a cautious "Hold" rating with a consensus target price of $102.70 for Zimmer Biomet.

https://www.marketbeat.com/instant-alerts/filing-first-national-bank-of-omaha-takes-892-million-position-in-zimmer-biomet-holdings-inc-zbh-2026-06-13/

Picard Medical (PMI) asks shareholders to approve reverse split, 15M Class B shares

Picard Medical (PMI) is asking shareholders to approve a reverse stock split at a ratio of 1-for-15 to 1-for-50 and to designate 15,000,000 shares of Class B common stock with 20 votes per share at its virtual Annual Meeting on July 17, 2026. The reverse split is aimed at addressing NYSE American non-compliance issues related to stockholders' equity, while the Class B shares seek to provide flexibility for future equity issuances and strategic transactions. The Board believes these measures are in the best interest of the company and its stockholders, though the implementation of both proposals is at the Board's discretion.

https://www.stocktitan.net/sec-filings/PMI/pre-14a-picard-medical-inc-preliminary-proxy-statement-23a2a689e07a.html

Sector Gamma AS Acquires 23,422 Shares of Edwards Lifesciences Corporation $EW

Sector Gamma AS increased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 32.1% in the recent quarter, acquiring an additional 23,422 shares, bringing their total to 96,402 shares valued at $8.22 million. Other institutional investors have also adjusted their positions in the medical research company, which currently has a "Moderate Buy" consensus rating from analysts. Recent insider stock sales by company VPs Daniel J. Lippis and Donald E. Bobo, Jr. were also noted.

https://www.marketbeat.com/instant-alerts/filing-sector-gamma-as-acquires-23422-shares-of-edwards-lifesciences-corporation-ew-2026-06-12/

Trending Today

Align Technology Inc. ($ALGN) Stock Forecast: Up 5.2% Today

Grab Holdings Limited ($GRAB) Stock Forecast: Up 7.1% Today

Electronic Arts Inc. ($EA) Stock Forecast: Down 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.0% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.6% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.2% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Up 5.6% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.3% Today

Edwards Lifesciences Corporation Price History

31.02.2026 - EW Stock was down 3.4%

• The bearish movement in Edwards Lifesciences Corp. (EW) stock can be attributed to profit-taking by investors after a period of sustained growth.
• Despite positive developments such as the FDA clearance for the AI heart valve repair solution developed in collaboration with Philips, the market may have reacted negatively due to high expectations already priced into the stock.
• The positive 2-year survival data from the TRISCEND II trial for the EVOQUE transcatheter tricuspid valve replacement system could have been overshadowed by broader market sentiment or sector rotation.
• Investors might be cautious about the stock's valuation, considering the recent price pressure and fluctuations, leading to the bearish movement despite the company's strong management efficiency and positive long-term performance.

16.05.2026 - EW Stock was up 5.1%

• Edwards Lifesciences Corp. (EW) experienced a noteworthy increase in its stock price, surpassing the broader market indices.
• Sector Gamma AS and other institutional investors acquiring additional shares in EW could be seen as a vote of confidence in the company's future outlook.
• The favorable sentiment towards EW might be linked to anticipated progress in heart valve technology or positive advancements in the company's pipeline.
• Despite the upward trend, the stock exhibited lower performance compared to the overall market, suggesting potential for further growth and opportunities for market catch-up.

11.01.2026 - EW Stock was up 1.1%

• An affirmation of a "Buy" rating for Edwards Lifesciences (EW) with a target price of $103.00 USD has enhanced investor confidence and sparked a bullish movement in the stock.
• Despite falling short of the EPS estimate by $0.04, Edwards Lifesciences delivered robust Q4 2025 sales growth, primarily from TAVR sales, and expressed optimism about its 2026 adjusted EPS and full-year sales growth forecast. This positive outlook has likely contributed to the bullish momentum.
• Strong Q4 2025 results, featuring double-digit revenue growth and positive projections for growth avenues like the LAA market, have reinforced investor confidence in Edwards Lifesciences, adding fuel to the bullish trend.
• Overall, positive analyst ratings, robust sales growth, and a promising future outlook have driven Edwards Lifesciences' stock on an upward trajectory today.

24.03.2026 - EW Stock was up 5.0%

• Despite surpassing Q1 earnings expectations and showing robust revenue growth, the market response was mixed as its Q2 and full-year outlook aligned with predictions.
• Selling activities from institutions like Teacher Retirement System of Texas and OLD National Bancorp IN, along with insider trading, might have contributed to short-term selling pressure on the stock.
• Analysts' differing views and adjustments to price targets indicate uncertainty and possible market volatility.
• The stock price target increase by Truist Securities, citing strong growth in Transcatheter Aortic Valve Replacement (TAVR) and improved revenue and earnings guidance, likely influenced the upward movement.

24.03.2026 - EW Stock was up 6.0%

• An analyst reiterated a Buy rating and raised the price target for Edwards Lifesciences following its strong Q1 results, which has positively impacted investor sentiment.
• The company has increased its full-year guidance, noting better-than-expected performance in Q1, particularly in its transcatheter aortic valve replacement (TAVR) business, driving sales growth.
• Despite some selling from insiders and institutions, likely due to profit-taking concerns related to the high P/E ratio, overall market sentiment remains positive, with many analysts revising price targets upwards, indicating confidence in the company's future.
• The market response to the guidance meeting consensus expectations may result in short-term selling pressure, but the company's solid performance and growth prospects suggest a favorable trajectory for Edwards Lifesciences.

27.02.2026 - EW Stock was down 5.3%

• Edwards Lifesciences (EW) witnessed a downward trend despite recent positive developments related to Vanguard subsidiaries' holdings in the company.
• Market sentiment towards medical device firms, exacerbated by enVVeno Medical Corp's strategic shift and regulatory hurdles, likely affected Edwards Lifesciences' stock performance.
• Heightened investor attention on Abbott Laboratories' stock following a slowdown in diagnostics may have contributed to the bearish movement in the medical technology sector, impacting companies like Edwards Lifesciences.
• Although outperforming competitors on a recent trading day, prevailing market conditions and sector-specific obstacles appear to have overshadowed the positive momentum for Edwards Lifesciences, resulting in the downward movement.

27.02.2026 - EW Stock was down 5.1%

• The bullish movement in AstraZeneca's shares could have attracted investors away from Edwards Lifesciences, impacting its stock negatively.
• The positive projections for the global cardiac ablation devices market might have shifted investor focus towards competitors in the healthcare sector, leading to a bearish trend for Edwards Lifesciences.
• Information about Vanguard reporting zero holdings in Edwards Lifesciences could have caused uncertainty among investors, contributing to the bearish movement in the stock.
• The strategic shift and challenges faced by enVVeno Medical Corp could have highlighted the competitive landscape in the healthcare industry, potentially affecting investor sentiment towards companies like Edwards Lifesciences.

28.03.2026 - EW Stock was down 3.0%

• Profit-taking by investors after a recent strong trading day has contributed to the bearish movement in Edwards Lifesciences (EW) stock.
• Concerns among investors about potential competition in the cardiovascular space, triggered by the pending acquisition of Penumbra by Boston Scientific, have negatively impacted EW's stock.
• Market sentiment surrounding broader industry developments, despite positive news like the CEO's upcoming presentation and increased holdings by Munich Reinsurance Co Stock Corp, has influenced the bearish movement in EW stock today.